{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:53:56Z","timestamp":1778633636415,"version":"3.51.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with platinum-resistant recurrent high grade serous ovarian carcinoma have poor outcomes and limited treatment options.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We present a case of a 48-year-old woman with platinum-resistant high grade serous ovarian carcinoma harboring the pathogenic <jats:italic>TSC2<\/jats:italic> R611Q variant with concomitant single copy loss of <jats:italic>TSC2<\/jats:italic> (suggesting biallelic <jats:italic>TSC2<\/jats:italic> inactivation) identified in targeted tumor sequencing. The patient was treated with the mTOR inhibitor everolimus, with an excellent response by imaging and a marked decrease in CA125; she remained on everolimus for 19 months until she developed progressive disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While mTOR inhibition is frequently used in tumors associated with tuberous sclerosis complex (TSC), such as lymphangioleiomyomatosis and malignant perivascular epithelioid cell tumors, this is the first case of a patient with ovarian cancer harboring <jats:italic>TSC1\/2<\/jats:italic> mutations who responded to mTOR inhibition. This case highlights the utility of targeted DNA sequencing in the management of ovarian carcinoma and demonstrates the value of tumor-agnostic targeted therapies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1357980","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T05:12:50Z","timestamp":1711516370000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Response to everolimus in a patient with platinum resistant, high grade serous ovarian carcinoma with biallelic TSC2 inactivation"],"prefix":"10.3389","volume":"14","author":[{"given":"Mariko","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Kolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis A.","family":"Konstantinopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00617-9","article-title":"Clinical and translational advances in ovarian cancer therapy","volume":"4","author":"Konstantinopoulos","year":"2023","journal-title":"Nat Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discovery"},{"key":"B4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clinbiochem.2018.08.003","article-title":"Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up","volume":"60","author":"Ferraro","year":"2018","journal-title":"Clin Biochem"},{"key":"B5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/13543784.2021.1939305","article-title":"Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies","volume":"30","author":"Leung","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 complex: a molecular switchboard controlling cell growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.2981","article-title":"Clinical activity of mTOR inhibition with sirolimus in Malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors","volume":"28","author":"Wagner","year":"2010","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres","article-title":"Treatment of advanced Malignant uterine perivascular epithelioid cell tumor with mTOR inhibitors: single-institution experience and review of the literature","volume":"36","author":"Starbuck","year":"2016","journal-title":"Anticancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00922-7","article-title":"TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition","volume":"35","author":"Chiang","year":"2022","journal-title":"Mod Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of oncoPanel: A targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS597","article-title":"Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with Malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)","volume":"41","author":"Iyer","year":"2023","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.10.029","article-title":"Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer","volume":"156","author":"Taylor","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6475","article-title":"A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers","volume":"12","author":"Starks","year":"2023","journal-title":"Cancer Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22951","article-title":"Variants within TSC2 exons 25 and 31 are very unlikely to cause clinically diagnosable tuberous sclerosis","volume":"37","author":"Ekong","year":"2016","journal-title":"Hum Mutat"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","article-title":"STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12885-017-3440-0","article-title":"The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole","volume":"17","author":"George","year":"2017","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.11.030","article-title":"Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors","volume":"152","author":"Stanley","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.04.020","article-title":"Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers","volume":"146","author":"Colon-Otero","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"x3","DOI":"10.1093\/annonc\/mdz281","article-title":"Overview of the relevance of PI3K pathway in HR-positive breast cancer","volume":"30","author":"Vasan","year":"2019","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/01.ogx.0000943180.30391.de","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"LBA5507","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507","article-title":"Phase III MIRASOL (GOG 3045\/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression","volume":"41","author":"Moore","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1357980\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T05:12:52Z","timestamp":1711516372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1357980\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":26,"alternative-id":["10.3389\/fonc.2024.1357980"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1357980","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"article-number":"1357980"}}